Associate Professor, Department of Hematopathology, MD Anderson Cancer Center, USA, pathCast · 1 lecture here
Compares WHO and ICC classification systems for diagnosing acute myeloid leukemia and myelodysplastic neoplasms.
Read moreShow fewer
Hematopathology diagnosis integrates the WHO fifth edition and International Consensus Classification systems for acute myeloid leukemia and myelodysplastic neoplasms. Sanam Loghavi examines shifts in nomenclature, genetic disease definitions, and prognostic implications of alterations in TP53, SF3B1, and CEBPA. Case examples illustrate classification dilemmas, variant allele frequency cutoffs, and morphologic findings across different diagnostic thresholds. The session concludes by comparing risk stratification frameworks and highlighting clinical trial eligibility impacts.
Compares WHO and ICC classification systems for diagnosing acute myeloid leukemia and myelodysplastic neoplasms.
Hematopathology diagnosis integrates the WHO fifth edition and International Consensus Classification systems for acute myeloid leukemia and myelodysplastic neoplasms. Sanam Loghavi examines shifts in nomenclature, genetic disease definitions, and prognostic implications of alterations in TP53, SF3B1, and CEBPA. Case examples illustrate classification dilemmas, variant allele frequency cutoffs, and morphologic findings across different diagnostic thresholds. The session concludes by comparing risk stratification frameworks and highlighting clinical trial eligibility impacts.
Is it for you
Summary written with AI from the lecture and its description
What you will take away
1MDS is now categorized using a hierarchical system driven by genetic abnormalities or morphologic criteria.
2Biallelic or multi-hit TP53 inactivation carries significant prognostic weight in myelodysplastic syndromes.
3Variant allele frequency thresholds for SF3B1 mutations differ between WHO and ICC criteria.
4Therapy-related myeloid neoplasms retain distinct categorization in WHO but factor into genetic sorting in ICC.
5ELN risk stratification relies heavily on initial molecular genetics rather than older blast ratios.
Before you start
Good fit if
Pathologists and hematology fellows who need a working knowledge of the 5th edition WHO and ICC diagnostic criteria for myeloid neoplasms. Explains the material in order, conversational in tone and warm toward the audience. Takes questions along the way.
Keep goingTargeting Apoptosis in Leukemia: Lessons and Challenges (Yale Cancer Center Grand Rounds)Shared subfield · Hematology & Oncology & Leukemia, Lymphoma & Myeloma
#HEMEPATH Navigating Change and Integrating WHO 5th/ ICC Classification Systems in the diagnosis …
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. The ring is what it teaches. People and places are above. Other lectures and books are below.